SEC Form 4 · accession 0001209191-18-009256
Atara Biotherapeutics, Inc. · ATRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Isaac E. Ciechanover
Officer — Chief Executive Officer · Director
Period of report
Feb 8, 2018
Accepted (ET)
Feb 12, 2018 · 5:09 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001604464
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2,F3 | Feb 8, 2018 | S | 4,400 | $37.15 | D | 287,278 | I | See footnote |
| Common StockF4,F3 | Feb 9, 2018 | S | 2,200 | $36.59 | D | 285,078 | I | See footnote |
| Common StockF5,F3 | Feb 9, 2018 | S | 1,100 | $37.43 | D | 283,978 | I | See footnote |
| Common StockF6,F3 | Feb 9, 2018 | S | 400 | $38.68 | D | 283,578 | I | See footnote |
| Common StockF7,F3 | Feb 9, 2018 | S | 400 | $40.79 | D | 283,178 | I | See footnote |
| Common StockF3 | Feb 9, 2018 | S | 300 | $41.70 | D | 282,878 | I | See footnote |
| Common Stock | holding | — | — | — | 808,675 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Transaction pursuant to Rule 10b5-1 Plan adopted May 18, 2017.
- F2The price in Column 4 is a weighted average sale price. The prices actually received ranged from $36.80 to $37.50. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F3Shares are held by the Isaac E. Ciechanover and Allison M. Ciechanover Family Trust dated 8/8/08, of which the Reporting Person is a trustee.
- F4The price in Column 4 is a weighted average sale price. The prices actually received ranged from $35.95 to $36.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F5The price in Column 4 is a weighted average sale price. The prices actually received ranged from $37.00 to $38.00. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F6The price in Column 4 is a weighted average sale price. The prices actually received ranged from $38.50 to $39.20 The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
- F7The price in Column 4 is a weighted average sale price. The prices actually received ranged from $40.30 to $40.95. The reporting person will provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.